# US 2025/0375377 A1 · Opioid independent surgical anesthetic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375377 A1
- Document ID: US20250375377A1
- Status: Published application
- Kind: A1
- Application number: 19/309,843
- Filed: 2025-08-26
- Published: 2025-12-11
- Earliest claimed: 2019-09-13
- Applicants: University of Utah Research Foundation
- Inventors: Brett Davis; Andrew M. Simpson; Jayant P. Agarwal; Jill E. Shea; Himanshu Jayant Sant; Bruce K. Gale
- Web page: https://patentgrep.com/patent/US20250375377A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An opioid independent surgical anesthetic composition includes an injectable dosage form of a hydrogel having a plurality of solid lipid matrix particles entrapped therein. The solid lipid matrix particles include a lipophilic local anesthetic drug and a lipid glyceride (e.g., saturated triglyceride or lipid blend of various lipid glycerides). Methods for creating a long-acting local anesthetic product can include creating a bulk solid of a lipid matrix product by heating a lipid solvent above its melting point, dissolving a lipophilic local anesthetic drug therein, reducing a temperature of the resultant drug-lipid solution to below the melting point of the lipid solvent, and heat annealing the lipid matrix to remove or reduce presence of any unstable polymorphs in the lipid matrix. The methods can further include crushing the bulk solid of the lipid matrix product to form solid lipid matrix particles and entrapping the solid lipid matrix particles within a hydrogel.

## Claims

### Claim 1

A method for creating a long-acting local anesthetic product, comprising:
creating a bulk solid of a lipid matrix product by:
heating a lipid solvent above a melting point of the lipid solvent;
dissolving a lipophilic local anesthetic drug into the lipid solvent to form a drug-lipid solution;
reducing a temperature of the drug-lipid solution to below the melting point of the lipid solvent; and
heat annealing the lipid matrix to remove or reduce presence of any unstable polymorphs in the lipid matrix;
forming solid lipid matrix particles by crushing the bulk solid of the lipid matrix product; and
entrapping a plurality of the solid lipid matrix particles within a hydrogel.

### Claim 2 (depends on 1)

The method of claim 1, wherein creating the bulk solid of the lipid matrix product comprises quenching the drug-lipid solution to ambient temperature or below when reducing the temperature of the drug-lipid solution to below the melting point of the lipid solvent, such quenching being followed by the heat annealing, wherein the heat annealing comprises heating and maintaining a temperature of the lipid matrix at approximately 8° C.-12° C. below the melting point of the lipid solvent for approximately one hour or longer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the lipophilic local anesthetic drug comprises bupivacaine, ropivacaine, lidocaine, or another amide based local anesthetic, wherein the lipid solvent comprises a lipid blend, and wherein the hydrogel comprises a cross-linked or non-cross-linked hyaluronic acid hydrogel.

### Claim 4

A method for administering an opioid independent surgical anesthetic composition, the composition comprising an injectable dosage form of a hydrogel having a plurality of solid lipid matrix particles entrapped therein, the plurality of solid lipid matrix particles comprising a lipophilic local anesthetic drug and a saturated glyceride, the method comprising topically applying the composition to a surgical or other wound bed, or injecting the composition via any of various routes.

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition is injected or otherwise delivered into an intrathecal space, an intra-articular space, another fluid-filled cavity, an ocular space, injected or otherwise delivered transdermally, orally, sub-cutaneously, intranasally, vaginally, buccally, epidurally, dentally, intratumorally, intramuscularly, or intravenously, on its own or in combination with another therapeutic agent.
